Skip to main content
Robert Wesolowski, MD, Oncology, Columbus, OH

RobertWesolowskiMD

Oncology Columbus, OH

Assistant Professor, Internal Medicine, Ohio State University College of Medicine

Dr. Wesolowski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Wesolowski's full profile

Already have an account?

  • Office

    460 W 10th Ave
    Columbus, OH 43210
    Phone+1 614-293-6529
    Fax+1 614-293-9429

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Internal Medicine, 2004 - 2007
  • State University of New York Downstate Medical Center College of Medicine
    State University of New York Downstate Medical Center College of MedicineClass of 2004

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2004 - 2025

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Modeling Combination Therapy for Breast Cancer with BET and Immune Checkpoint Inhibitors  
    Robert Wesolowski, Andrew Stiff, Proceedings of the National Academy of Sciences

Press Mentions

  • Bexion Pharmaceuticals, Inc. Announces Publication of Phase 1 Data for BXQ-350 in Advanced Solid Tumors
    Bexion Pharmaceuticals, Inc. Announces Publication of Phase 1 Data for BXQ-350 in Advanced Solid TumorsOctober 31st, 2024
  • Ohio State's Novel DHODH Inhibitor Enters First Human Trials
    Ohio State's Novel DHODH Inhibitor Enters First Human TrialsSeptember 16th, 2024
  • Sanofi’s, AstraZeneca’s and Radius’ Oral SERDs Could Establish Clinical Worth in ER+ Breast Cancer by Showing Similar Efficacy to Faslodex, Experts Say
    Sanofi’s, AstraZeneca’s and Radius’ Oral SERDs Could Establish Clinical Worth in ER+ Breast Cancer by Showing Similar Efficacy to Faslodex, Experts SayApril 6th, 2021
  • Join now to see all